Latest News and Press Releases

TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $100,000 pediatric research grant awarded to Dr. Cynthia Hawkins, neuropathologist-scientist, and her team at...

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to...

AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its Chief Executive Officer (“CEO”),...

AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary...

Low to ultra-low radio frequency energy signals (ulRFE®) are the basis of the new digital therapeutic innovation by EMTx BELLEVUE, Wash., April 18, 2023 (GLOBE NEWSWIRE) -- EMulate Therapeutics, a...

-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC)...

RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...

R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...

AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...